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Summary 
--------
Successful solid organ transplantation is generally attributed to the increas-
ingly precise ability of drugs to control rejection. However, it was recently shown 
that a few donor haematolymphoid cells can survive for decades in recipients of 
successful organ allografts, a phenomenon called microchimaerism. The associ-
ation for decades of haematolymphoid chimaerism with allograft tolerance in 
experimental transplantation suggests that immunosuppressive drugs merely cre-
ate a milieu that enables an allograft and its complement of passenger leucocytes 
to prime the recipient for graft acceptance. 
Exploitation of this concept requires a fundamental shift in the classical view 
of passenger leucocytes only as initiators of rejection. Microchimaerism has 
taught us that solid organ transplantation involves the transfer of two donor organ 
systems to the recipient: the allograft parenchyma and the donor haemato-
lymphoid system in the form of donor stem cells contained within the passenger 
leucocyte compartment. Each has the potential to integrate with the correspond-
ing recipient system and carry out normal physiological functions, such as im-
munological self definition. Resistance to initial integration by mature T cells 
requires some form of immunosuppression, but maintenance of donor immune 
system function will depend on renewable supply of cells, which can be provided 
by engrafted progenitors. Successful clinical application will depend on the de-
velopment of low morbidity methods to enhance engraftment of donor haemo-
poietic stem cells. 
------- ----
------------------------------------- ------
The recent success of solid organ transplanta-
tion is generally attributed to the increasingly pre-
cise ability of drugs such as cyclosporin, and more 
recently tacrolimus, to control rejection by inhibit-
ing signal transduction in activated T lympho-
cytes.[l·2] However, the observation that these or 
other drugs can control allograft rejection and pro-
long graft survival does not imply that, alone, they 
are capable of inducing donor-specific tolerance. 
In fact, most solid allograft recipients seem to uni-
formly require lifelong immunosuppressive ther-
apy to maintain graft function. In this paper, we 
describe recent evidence suggesting that immuno-
suppressive drugs create a milieu which allows an 
allograft to prime the recipient for the induction of 
allogeneic tolerance. We suggest that every solid 
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organ allograft transplanted under the cover of im-
munosuppression has this potential to induce toler-
ance. 
1. Donor-Specific Tolerance 
Acquired donor-specific transplantation tolerance 
was first observed in cattle twins,l3] and was then 
intentionally induced over 40 years ago in experi-
mental animal fetuses exposed to allogeneic haem-
atolymphoid cells.l41 Tolerance in this setting was 
associated with mixed haematolymphoid chimaer-
ism, a condition in which a single functionally in-
tegrated immune system is composed of cells from 
two different individuals. 
Since the early experimental successes, many 
investigators have attempted to replicate this situ-
ation in adults in a clinically applicable setting.l5-121 
Conditioning, or ablating, the recipient's immune 
system with cytoreductive drugs or irradiation, and 
then infusing donor haematolymphoid cells, re-
sults in engraftment of a significant number of the 
infused donor stem cellsJ5-12] This results in the 
creation of a chimaeric immune system and, even-
tually, in the development of complete donor-
specific tolerance, including unresponsiveness in 
in vitro assays of immunological reactivity, such as 
the mixed lymphocyte reaction. 
In such animals, tolerance is associated with 
easily detectable chimerism (usually> 1 %) and is 
dependent on the persistence of donor haemato-
lymphoid cells - remove the donor cells and the 
tolerance is lost.[12-17] Immunological mechanisms 
involved include 'central' pathways of clonal dele-
tion,[IS] presumably brought about by the presence 
of donor dendritic cells in the thymus during T cell 
development, a point elegantly illustrated in stud-
ies of intrathymic tissue transplantation.l18,19] In-
sertion of a complete islet tissue allograft into the 
thymus results in a state of systemic donor-specific 
tolerance.l18.191 However, if the intrathymic graft is 
first depleted of passenger leucocytes, rendering it 
'nonimmunogenic', a subsequent extrathymic graft 
is rejected,[20,21] even though the intrathymic im-
plant survives. Lastly, although central pathways 
have received the most attention, 'peripheral' reg-
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ulatory control of donor reactive cells that escape 
thymic deletion has also been detected.l l51 
Regardless of the mechanisms involved, com-
plete and permanent tolerance to a variety of organs 
has been routinely produced in a variety of exper-
imental settings using myeloablation and bone 
marrow transplantation.[5-12,22] However, the high 
morbidity and mortality associated with the condi-
tioning regimes, in conjunction with the added risk 
of graft-versus-host disease, have prevented these 
strategies from being routinely applied in a clinical 
setting. 
2. Persistence of Passenger Leucocytes 
Solid organ transplantation gradually became a 
clinical succes, even without the treatment strate-
gies that produced an ideal outcome in experimen-
tal models. Although the underpinnings of this suc-
cess were thought to be the increasingly precise 
immunosuppressive drugs, a recent discovery has 
suggested that drugs only provide the milieu for a 
biological process that had been experimentally 
shown to be highly tolerogenic. 
This discovery was that passenger leucocytes, 
or donor non-parenchymal leucocytes contained 
within the stroma of all organs, were found to per-
sist in small numbers (usually less than 1 : 1000) 
throughout recipient tissues for decades after suc-
cessful solid organ transplantation.l23-25] The same 
observations were made in experimental animals, [26,27] 
even if they spontaneously accepted allografts with-
out immunosuppressionPSj 
Classically, passenger leucocytes had been 
viewed only as initiators of rejection, because of 
their proven role as stimulators of the alloreac-
tion.[291 Their persistence in the tissues oflong term 
organ allograft recipients had escaped notice be-
cause few had actually looked for them, and newer 
sophisticated techniques were required for their de-
tection. However, their presence after solid organ 
transplantation is analogous to the mixed haemato-
lymphoid chimserism which has been associated 
with allogeneic tolerance for many yearsJ41 It is 
thought that the major differences between the two 
forms of chimaerism appear to be the number of 
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donor cells circulating in the recipient, and possibly 
the location of progenitor cells. 
3. Clinical Observations on Withdrawal 
of Immunosuppression 
The development oftacrolimus, with its power-
ful ability to reverse acute rejectionPO] made it 
possible to attempt withdrawal ofimmunosuppres-
sive drugs from long-surviving liver allograft re-
cipients,f3l] in whom persistent donor passenger 
leucocytes had been found. The entry criteria used 
were: 
• 5 years post-transplant 
• 2 years without rejection 
• good history of compliance 
• immunosuppression-related complications 
• baseline liver biopsy showing freedom from re-
jection and disease. 
59 patients were gradually weaned from a vari-
ety of immunosuppressive regimens. Complete 
weaning was accomplished in 27.1 % with 3 to 19 
months of drug-free follow-up. Drug weaning was 
progressing in 47.4%, but had failed in 25.4% al-
though there were no graft losses or irreversible 
damage. It was notable that the ease with which 
patients could be weaned off immunosuppression 
was independent of their starting regimen, suggest-
ing the effect to be independent of drug type. How-
ever, successful weaning in this situation appeared 
to be dependent on a slow staged withdrawal of 
drugs (unpublished observation). Such studies 
show that solid organ allograft transplantation un-
der the cover of immunosuppression can eventu-
ally result in allograft acceptance without the need 
for continued immunosuppressive treatment. 
The exact mechanism of allogeneic tolerance 
induction in this setting has not been defined, but 
clonal deletion is usually not evident and donor-
specific reactivity in a mixed lymphocyte reaction 
may be depressed, although usually detectable.[32-34J 
This may be related to the small number of persist-
ent donor haematolymphoid cells, with few keep-
ing residence in the thymus,[27] although mainte-
nance of thymic function does not seem to be 
necessary in this circumstance.[35J These observa-
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tions suggest that peripheral or immune regulatory 
pathways are likely to playa significant role in the 
maintenance of allograft function, although a com-
ponent of central control or deletion cannot be en-
tirely excluded. 
In particular, we have been interested in periph-
eral regulation as an active phenomenon, based on 
the immune network theory initially proposed by 
Jerne[36J and furthered by Coutinho,l37,38] It is pos-
sible that the donor cells set up a self-referential 
system that successfully integrates into the recipi-
ent immune network in patients who are able to be 
successfully weaned from drugs. Such a system 
would include anti-idiotypic clones of recipient T 
and B cells (anti-self), produced as part of the re-
sponse to donor alloantigenP9] In this line of rea-
soning, rejection or an alloreaction is the signal for 
tolerance induction, and control of the immune re-
sponse involves autoregulatory or 'autoimmune' 
reactions. Thus, without an alloresponse or rejec-
tion, there will be no tolerance. 
To date, the majority of patients who have been 
successfully weaned from immunosuppression are 
liver allograft recipients who were on potent im-
munosuppression for many years. Similar weaning 
protocols have been less successful after kidney 
transplantation, and suggest that the liver may be 
more tolerogenic (section 4))40J Working retro-
spectively through the data to determine what fac-
tors, if any, are common to these patients other than 
haematolymphoid chimaerism is certainly a worthy 
goal. However, such a process would take many 
years and may even produce equivocal or confus-
ing results. Since it is already known from experi-
mental studies that chimaerism is necessary for the 
maintenance of tolerance, it may be more useful to 
examine the actions of immunosuppressive drugs 
and events that occur after organ transplantation to 
identify potential points of therapeutic intervention. 
4. Potential Points of 
Therapeutic Intervention 
In the absence of immunosuppression, multi-
lineage passenger leucocytes contained within the 
allograft disseminate by haematogenous migratory 
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routes,[27,4l) and can be found throughout the pri-
mary lymphoid organs of the recipient within 24 
hours. l42,431 The number and type of donor cells 
that leave the allograft is dependent on the organ 
transpianted.l40) Tolerogenic bone marrow and liver 
allografts are rich in haemopoietic stem cells. l441 In 
fact, an adult liver allograft flushed free of blood 
by preservation fluid can completely reconstitute 
the haematolymphoid system of a lethally irradi-
ated syngeneic recipient.[441 Other allografts that 
are less tolerogenic, such as the heart, are stem cell 
poor[441 and organs like the intestines, which regu-
larly cause graft-versus-host disease when trans-
planted, are T cell rich.l40] 
Recipient haematolymphoid cells also enter the 
allograft, where T cell infiltration can be docu-
mented within 48 hours of transplantation.l43 ,451 
Mixing of donor and recipient immunocompetent 
cells at these 'central' and 'peripheral' sites results 
in an in vivo equivalent of a mixed lymphocyte 
reaction that is initiated by dendritic cells and al-
logeneic T ceHs.l43,451 This causes T cell activation 
within 24 to 48 hours, secretion of cytokines and 
initiation of effector cascades capable of destroy-
ing the organ, such as cytotoxic T lymphocytes and 
aHo-antibodies. For these reasons, passenger leuco-
cytes have been considered deleterious to allograft 
survival. However, this fate can be dramatically 
altered by administering an immunosuppressive 
agent. 
With the exception of transplants between a lim-
ited number of experimental animal strains,[27.28,46) 
some form of at least transient immunosuppressive 
control is essential both for survival of the allograft 
and subsequent induction of tolerance. However, 
the exact site of drug action appears to be irrelevant 
- whether at the level of antigen presentation [gus-
perimus (deoxyspergualin)], gene transcription 
(tacrolimus, cyclosporin), cytokine action [sirolimus 
(rapamycin)] or clonal expansion and inhibition of 
DNA synthesis (azathioprine, mizoribine, cyclo-
phosphamide and mycophenolate mofetil). Con-
trol of the alloreaction can also be achieved with 
monoclonal antibodies to a variety of antigens, in-
cluding CD4, adhesion molecules and the interleu-
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kin-2 receptor.f47,481 In fact, as reviewed recently,[47,48] 
every potent immunosuppressant studied has been 
claimed to induce tolerance in some experimental 
system. Thus, it is likely that the common end re-
sult seen with all of these drugs is related to a per-
missive effect, rather than a variety of separate 
causative effects, that facilitates the migration and 
survival of donor passenger leucocytes and modu-
lates the context of allorecognition,l25.27.28,39.491 
In order to exploit this knowledge, however, a 
fundamental shift in our thinking must occur.f391 It 
is tacitly accepted that an orthotopic solid organ 
allograft integrates into the appropriate physiolog-
ical system of the recipient. For example, a newly 
transplanted liver accepts nutrients absorbed by al-
logeneic intestines and then secretes serum pro-
teins utilised by the remainder of the body. The 
allograft also secretes bile, manufactures choles-
terol and, altogether, it is really no surprise that the 
organ is carrying out its normal physiological func-
tions in an allogeneic environment. Microchimaer-
ism has taught us that solid organ transplantation 
involves the transfer of two donor organ systems to 
the recipient - the organ itself and the seeds or essence 
of the donor haematolymphoid system.l44] Like the 
allograft parenchyma, the donor haematolymphoid 
system has the potential to integrate with the recip-
ient and carry out some of its normal physiological 
functions, although this integration is resisted 
by the mature elements (especially T cells) in both 
populations. Thus, the initial encounter requires 
immunosuppression or deletion of the T cells. There-
after, successful integration will depend on contin-
ual supply of donor haematolymphoid cells, which 
can be provided hy engrafted progenitors. Success-
ful introduction of a few new donor peptides on 
major histocompatibility complex (MHC) mole-
cules into the existing recipient immune network 
can have profound immunological consequences. 
Hypothetical outcomes of this integration would 
include: (a) establishing a new profile of resistance 
to infection and autoimmune disorders; and (b) an 
ability to react to allogeneic but not syngeneic tissues. 
There has been recent discussion, and even sanc-
tioned debate, on whether the parenchyma of the 
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Table I. Potential mechanisms by which immunosuppressive drugs might promote the induction of allograft tolerance 
Mechanism Agents 
Attenuate rejection, thereby preventing destruction of allogeneic donor passenger leucocytes in 
the recipient lymphoid and non lymphoid tissues 
Not drug-specific 
Allow B cell activation (in response to surviving donor cell surface antigens) which may 
contribute to network control of the immune system" 
Not drug-specific 
Increase thymic accrual of donor dendritic cells, allowing exposure of the immature host 
immune system to donor alloantigens 
Tacrolimus, cyclosporinl50,51 j 
Allow movement of immature thymocytes to the periphery, resulting in further exposure of 
immature T cells to donor alloantigens 
Tacrolimus, cyclosporinl52] 
Permit replication and widespread dispersal of the donor passenger leucocyte population, with 
consequent continuous presentation of donor alloantigen to the recipient immune system" 
Not drug-specific 
Inhibit the second signal required for activation of host lymphocytes presented with foreign 
alloantigen, thus promoting an anergic response 
Not drug-specific 
a Although not drug-specific, these mechanisms would appear to be dependent on the avoidance of overimmunosuppression, 
allograft or 'chimaerism' in the periphery is the key 
to maintenance of allograft acceptance. To us, this 
is a moot point and illustrates the need for a shift 
in perspective. In the broadest terms, any organ 
allograft recipient is chimaeric, although the cells 
accounting for the chimaerism may differ (paren-
chyma versus haematolymphoid cells). In fact, in 
both situations, donor antigen is present and can 
stimulate regulatory pathways of (or anergise) the 
recipient. However, it seems reasonable to con-
clude that the parenchyma is designed by nature for 
purposes other than tolerance induction, so it will 
not perform as well as haematolymphoid cells, an 
important function of which is the establishment of 
immunological boundaries. 
The mechanisms by which immunosuppressive 
drugs might directly or indirectly affect the recip-
ient response to donor passenger leucocytes have 
been described previously in some detail,[47] and 
are outlined in table I. Briefly, adequate immuno-
suppression prevents the early destruction of pas-
senger leucocytes that have migrated out of the al-
lograft, and allows their redistribution from the 
primary lymphoid organs throughout all tissues of 
the recipient.[27] Agents such as cyclosporin and 
tacrolimus can injure the thymic medulla and thus 
create a need for an emigration of dendritic cell 
progenitors, some of which may be supplied by 
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donor cells.[27,53,54] Exposing immature recipient T 
cells to potent donor MHC antigens during thymic 
selection increases the likelihood of clonal dele-
tion. These agents also increase the egress of im-
mature thymocytes into the periphery. In addition, 
the inhibition of antigen-presenting cell function 
caused by many immunosuppressants may block 
delivery of the second signal[55] and induce T cell 
anergy,[56] further contributed to by the continuous 
low grade antigenic stimulation caused by persist-
ing donor passenger leucocytes. 156,57] All of these 
hypothetical scenarios are dependent on a contin-
ual supply of immunogenic donor haematolymphoid 
cells, best satisfied by the transfer and engraftment 
of donor stem cells. Therefore, novel methods with 
low morbidity of enhancing engraftment of simul-
taneously transferred bone marrow cells should be 
the key to successful clinical application of this 
concept. 
5_ Experimental Links between 
Allo- and Auto-Immunity 
As mentioned in section 4, we are particularly 
interested in active regulatory control of allo-
reactivity as an important component in the toler-
ance observed after solid organ transplantation. 
Other evidence supporting the importance of low 
grade immune activity in the maintenance of toler-
Clin. Immunother. ]996 Aug; 6 (2) 
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ance has been provided by a recent report that 
showed that the interleukin-2 receptor ~ chain is 
required to keep the activation programmes of T 
cells under control. [581 Deletion of the gene for this 
receptor allowed loss of immune control, with con-
sequent death from autoimmunityJs8] 
To test whether transferred donor haemato-
lymphoid cells change other properties of the re-
cipient immune system, a series of experiments were 
carried out in the autoimmunity-prone Brown-
Norway (BN) rat, which develops autoreactive T 
cells after exposure to mercuric chloride. After a 
series of injections, BN rats develop systemic vas-
culitis, lymphocytic infiltration and damage to 
multiple visceral organs and the skin, polycIonal B 
cell activation and a host of autoantibodies. How-
ever, if the animal survives the acute syndrome and 
recovers, by immune regulation it becomes resis-
tant to further mercuric chloride injections. 
Lewis (LEW) rats do not develop clinical auto-
immune disease after injections of mercuric chlor-
ide. In BN rats made chimaeric (and tolerant to LEW 
grafts) by injection of allogeneic (LEW) bone mar-
row and transient immunosuppression, the contin-
ued presence of allogeneic cells was associated 
with low grade activation of the host immune sys-
tem.[591 More importantly, these animals were also 
resistant to the mercuric chloride injections, show-
ing that the presence of allogeneic cells triggered 
some of the same autoregulatory mechanisms in-
volved in alloimmunity. Reciprocal experiments 
carried out to determine the effect of autoimmunity 
on allogeneic tolerance induction have shown that 
cells capable of passively transferring resistance to 
mercuric chloride autoimmunity can also prolong 
allograft survival (CP Delaney et aI., unpublished 
observations ). 
6. Conclusions 
In summary, the simple answer to the question 
'can tolerance be achieved with immunosuppres-
sive treatment?' is 'yes', with the following caveats. 
First, too much immunosuppression is likely to be 
harmful to the process for the reasons outlined in 
sections 4 and 5. Second, despite the possibility of 
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inducing tolerance after solid organ transplantation 
with immunosuppression, currently only a minor-
ity of all allograft recipients can be weaned from 
therapy. The key to success is the development of 
low morbidity treatment modalities to enhance en-
graftment of haemopoietic stem cells transplanted 
as a part of the organ, or an additional inoculum of 
donor bone marrow. Thus, it is not an argument 
about whether the glass is half empty or half full, 
because nature has shown us that it is possible to 
fill the entire container. 
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